NCT05503953View on ClinicalTrials.gov

Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS

PHASE3UnknownINTERVENTIONAL
Enrollment

306

Participants

Timeline

Start Date

September 5, 2022

Primary Completion Date

February 29, 2024

Study Completion Date

July 31, 2024

Conditions
Essential Hypertension
Interventions
DRUG

AGSAVI

Uptitation

DRUG

AGLS

Uptitration

Sponsors
All Listed Sponsors
collaborator

Daehwa Pharmaceutical Co., Ltd.

INDUSTRY

lead

Ahn-Gook Pharmaceuticals Co.,Ltd

INDUSTRY

NCT05503953 - Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS | Biotech Hunter | Biotech Hunter